Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (September 2026)
25 slides from Proteomics International Laboratories's investor presentation, September 2026
Slide 1: Proteomics International Laboratories Ltd Investor Presentation
Proteomics International Laboratories Ltd Investor Presentation September 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia 0
Slide 2: Disclaimer
Disclaimer This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). This Presentation may contain forward-looking statements, including quantitative statements of anticipated future financial performance such as project
Slide 3: Executive Summary
INVESTMENT OVERVIEW Executive Summary Proteomics International is commercialising three clinically validated prognostic and diagnostic tests that address unmet clinical needs. With Healius appointed as its exclusive Australian pathology distributor, the Company is focused on executing the Australian
Slide 4: Why Proteomics
INVESTMENT HIGHLIGHTS Why Proteomics A multi-asset diagnostics portfolio at the point of commercial launch, with the distribution and reimbursement building blocks now in place. Three clinically validated tests, each addressing a long-standing diagnostic gap 1 Promarker Endo for endometriosis, where
Slide 5: Execution Plan – The Next 3 Years
STRATEGIC ROADMAP Execution Plan – The Next 3 Years The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. RESET ACCESS ADVANCE ACCELERATE ACHIEVE
Slide 6: Business and Portfolio
SECTION TWO Business and Portfolio Platform, products, addressable market, route to market and reimbursement 5
Slide 7: About Us
COMPANY OVERVIEW About Us Proteomics International integrates extensive proteomics knowledge with accredited laboratory operations to bring validated diagnostic solutions to market, improving patient outcomes through earlier and more precise diagnoses. Patient Advanced Test Complete Our Outcomes Dia
Slide 8: Innovation Portfolio – Four Tests
PORTFOLIO Innovation Portfolio – Four Tests Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical conditions. Promarker
Slide 9: Innovation Portfolio – Market Potential
PORTFOLIO Innovation Portfolio – Market Potential We have assessed the market opportunities for our three primary tests in both Australia and the United States. Our analysis indicates that the serviceable obtainable market opportunity is substantial, offering significant growth potential. Market Pot
Slide 10: Promarker D – Chronic Kidney Disease
PRODUCT OVERVIEW Promarker D – Chronic Kidney Disease Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Clinical Value Market Opportunity Key Actions Identifies hig
Slide 11: Promarker Eso – Oesophageal Cancer
PRODUCT OVERVIEW Promarker Eso – Oesophageal Cancer Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures. Clinical Value Market Opp
Slide 12: Promarker Endo – Endometriosis
PRODUCT OVERVIEW Promarker Endo – Endometriosis Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management. Clinical Value Market Opportunity Key Actions Identifies patients with a high risk of SOM reflects realistic m
Slide 13: Disciplined Path to Commercial Success
COMPANY OVERVIEW Disciplined Path to Commercial Success Proteomics International has shifted its emphasis to disciplined commercial execution, advancing a range of prognostic and diagnostic tests through clearly defined development phases, while maintaining strict control over capital management. Le
Slide 14: Distribution Partnerships to Accelerate Adoption
DISTRIBUTION MODEL Distribution Partnerships to Accelerate Adoption The distributor model delivers faster adoption, lower execution risk, and superior capital efficiency compared to any direct or hybrid alternative. Characteristics of the Distribution Model Key Success Factors • Builds upon experien
Slide 15: Exclusive Australian Distribution Agreement
ROUTE TO MARKET Exclusive Australian Distribution Agreement The agreement provides national pathology distribution for the full Promarker portfolio and removes the need to build a proprietary collection and referrer network in Australia. Key terms What the agreement changes Counterparty Healius Limi
Slide 16: Serviceable Market and Pricing per Test
MARKET OPPORTUNITY Serviceable Market and Pricing per Test Australian patient pricing is set for Promarker D and Promarker Eso, an indicative A$25 million per annum at serviceable obtainable volumes. Promarker Endo pricing follows completion of validation and would add 50,000 annual tests to that ba
Slide 17: Reimbursement Pathways – Australia
REIMBURSEMENT PATHWAYS Reimbursement Pathways – Australia Australia provides a national reimbursement framework for prognostic and diagnostic tests. Achieving Medicare Benefits Schedule (MBS) listing is a medium term objective that will serve as a significant driver of growth. Reimbursement Process
Slide 18: Reimbursement Pathways – USA
REIMBURSEMENT PATHWAYS Reimbursement Pathways – USA In the United States, reimbursement for prognostic and diagnostic tests is decentralised and based on evidence, growing incrementally through private and public funding. Reimbursement Process Key Considerations • The USA has no unified reimbursemen
Slide 19: Board of Directors
LEADERSHIP Board of Directors Dr James Williams Non- David Morris Aaron Brinkworth Paul House Vicki Robinson Executive CEO & Managing Non-Executive Director Non-Executive Director Non-Executive Director Chair Director BHIthSc, GAICD BEng (Hons), GAICD LLB (Hons), BCom, MAICD PhD, MBA, BSc (Hons) GAI
Slide 20: Appendix
APPENDIX Appendix 1 9
Slide 21: Science of Proteomics
PLATFORM Science of Proteomics The proteome offers a more complete view of disease than genomics. Turning biochemistry into validated prognostics and diagnostics requires precision, standardisation, and deep technical expertise. Complexity Requires Expertise What is Proteomics • Protein levels can s
Slide 22: Patient Care Ecosystem
PATIENT JOURNEY Patient Care Ecosystem The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to result. IDENTIFY COL
Slide 23: Strategic Framework for Execution
ENTERPRISE PRIORITIES Strategic Framework for Execution Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners, and investors.
Slide 24: OxiDx – Oxidative Stress Platform
PRODUCT OVERVIEW OxiDx – Oxidative Stress Platform Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits. Clinical Value Market Opportunity Key Actions Provides an objective measurement of SOM
Slide 25: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Proteomics International Laboratories — Investor Presentation (September 2026) on 6ix